Now showing items 1-5 of 5

    • Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial. 

      Sonnenblick, A; Bailey, A; Uziely, B; Untch, M; Smith, I; Gianni, L; Baselga, J; Jackisch, C; Cameron, D; Bell, R; Zardavas, D; Al-Sakaff, N; Gelber, RD; Dowsett, M; Leyland-Jones, B; Piccart-Gebhart, MJ; DE Azambuja, E (2019-02)
      BACKGROUND/AIM:This study sought to determine whether an autoimmune background could identify patients with HER2-positive early breast cancer (EBC) who derive differential benefit from primary adjuvant trastuzumab-based ...
    • Conducting non-commercial international clinical trials: the ICR-CTSU experience. 

      Fox, L; Toms, C; Kernaghan, S; Snowdon, C; Bliss, JM (2017-09-26)
      BACKGROUND:Academic clinical trials play a fundamental role in the development of new treatments, the repurposing of existing treatments and in addressing areas of unmet clinical need. With cancer treatments increasingly ...
    • Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. 

      Rosell, R; Dafni, U; Felip, E; Curioni-Fontecedro, A; Gautschi, O; Peters, S; Massutí, B; Palmero, R; Aix, SP; Carcereny, E; Früh, M; Pless, M; Popat, S; Kotsakis, A; Cuffe, S; Bidoli, P; Favaretto, A; Froesch, P; Reguart, N; Puente, J; Coate, L; Barlesi, F; Rauch, D; Thomas, M; Camps, C; Gómez-Codina, J; Majem, M; Porta, R; Shah, R; Hanrahan, E; Kammler, R; Ruepp, B; Rabaglio, M; Kassapian, M; Karachaliou, N; Tam, R; Shames, DS; Molina-Vila, MA; Stahel, RA; BELIEF collaborative group (2017-05)
      BACKGROUND:The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutations. The coexistence of the ...
    • International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. 

      Terpos, E; Morgan, G; Dimopoulos, MA; Drake, MT; Lentzsch, S; Raje, N; Sezer, O; García-Sanz, R; Shimizu, K; Turesson, I; Reiman, T; Jurczyszyn, A; Merlini, G; Spencer, A; Leleu, X; Cavo, M; Munshi, N; Rajkumar, SV; Durie, BGM; Roodman, GD (2013-06)
      The aim of the International Myeloma Working Group was to develop practice recommendations for the management of multiple myeloma (MM) -related bone disease.An interdisciplinary panel of clinical experts on MM and myeloma ...
    • Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. 

      Gautschi, O; Milia, J; Filleron, T; Wolf, J; Carbone, DP; Owen, D; Camidge, R; Narayanan, V; Doebele, RC; Besse, B; Remon-Masip, J; Janne, PA; Awad, MM; Peled, N; Byoung, C-C; Karp, DD; Van Den Heuvel, M; Wakelee, HA; Neal, JW; Mok, TSK; Yang, JCH; Ou, S-HI; Pall, G; Froesch, P; Zalcman, G; Gandara, DR; Riess, JW; Velcheti, V; Zeidler, K; Diebold, J; Früh, M; Michels, S; Monnet, I; Popat, S; Rosell, R; Karachaliou, N; Rothschild, SI; Shih, J-Y; Warth, A; Muley, T; Cabillic, F; Mazières, J; Drilon, A (2017-05)
      Purpose In addition to prospective trials for non-small-cell lung cancers (NSCLCs) that are driven by less common genomic alterations, registries provide complementary information on patient response to targeted therapies. ...